期刊
JOURNAL OF CLINICAL MEDICINE
卷 12, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/jcm12010162
关键词
ovarian cancer; anlotinib; cell proliferation; angiogenesis; apoptosis
In this study, the anti-tumor activity of Anlotinib, a new oral multi-targeted tyrosine kinase inhibitor, against ovarian cancer was investigated. Anlotinib inhibited the proliferation and migration of ovarian cancer cells in vitro, and suppressed tumor growth in a mouse ovarian carcinoma peritoneal metastasis model. These findings suggest that Anlotinib may be a promising therapeutic strategy for ovarian cancer.
Ovarian cancer remains the most common gynecologic malignancy, because of its chemotherapy resistance and relapse. Anlotinib, a new oral multi-targeted tyrosine kinase inhibitor, has shown encouraging antitumor activity in several preclinical and clinical trials, while its effect on ovarian cancer has not been reported. In this study, we investigated the antitumor activity and underlying mechanism of anlotinib in ovarian cancer. Cell viability was analyzed by Cell Counting Kit-8 assay. Migration was measured by wound-healing assay. The cell cycle distribution and cell apoptosis rate were detected by flow cytometry. In vivo antitumor effect was analyzed in mouse ovarian carcinoma peritoneal metastasis model. We found that anlotinib inhibited the proliferation of ovarian cancer cells in a dose- and time- dependent manner by inducing G2/M phase arrest and apoptosis. Moreover, anlotinib upregulated the the phosphorylation of Histone H3, and expression of p21 protein in vitro. In addition, anlotinib inhibited the migration of ovarian cancer cells in vitro. Furthermore, anlotinib inhibited tumor growth by inhibiting cell proliferation and suppressing ovarian cancer angiogenesis in vivo. This study demonstrated the extraordinary anti-ovarian cancer effect of anlotinib, which may provide a promising therapeutic strategy for ovarian cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据